Loss of TSLC1 expression in lung adenocarcinoma: Relationships with histological subtypes, sex and prognostic significance

Cancer Science

Volumn 96, Issue 8, 2005, Pages 480-486

  Goto, Akiteru ^a   Niki, Toshiro ^b   Chi Pin, Li ^a   Matsubara, Daisuke ^c   Murakami, Yoshinori ^d   Funata, Nobuaki ^e   Fukayama, Masashi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^e TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROTEIN P27; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; BRONCHIOLE; BRONCHUS MUCOSA; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CELL ADHESION; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; EPITHELIUM CELL; FEMALE; FREQUENCY ANALYSIS; GENDER; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SEX DIFFERENCE;

ADENOCARCINOMA; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOGLOBULINS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; NEOPLASM METASTASIS; PROGNOSIS; SEX CHARACTERISTICS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 25844465834     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2005.00075.x     Document Type: Article

References (26)

1. Kuramochi M, Fukuhara H, Nobukuni T et al. TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet 2001; 27: 427-30.
2. Murakami Y. Functional cloning of a tumor suppressor gene, TSLC1, in human non-small cell lung cancer. Oncogene 2002; 21: 6936-48.
3. Masuda M, Yageta M, Fukuhara H et al. The tumor suppressor protein TSLC1 is involved in cell-cell adhesion. J Biol Chem 2002; 277: 31 014-19.
4. Fukami T, Fukuhara H, Kuramochi M et al. Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines. Int J Cancer 2003; 107: 53-9.
5. Tamura G. Promoter methylation status of tumor suppressor and tumor-related genes in neoplastic and non-neoplastic gastric epithelia. Histol Histopathol 2004; 19: 221-8.
6. Honda T, Tamura G, Waki T et al. Hypermethylation of the TSLC1 gene promoter in primary gastric cancers and gastric cancer cell lines. Jpn J Cancer Res 2002; 93: 857-60.
7. Jansen M, Fukushima N, Rosty C et al. Aberrant methylation of the 5′ CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanINs. Cancer Biol Ther 2002; 1: 293-6.
8. Allinen M, Peri L, Kujala S et al. Analysis of 11q21-24 loss of heterozygosity candidate target genes in breast cancer: indications of TSLC1 promoter hypermethylation. Genes Chromosomes Cancer 2002; 34: 384-9.
9. Hui AB, Lo KW, Kwong J et al. Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma. Mol Carcinog 2003; 38: 170-8.
10. Fukuhara H, Kuramochi M, Fukami T et al. Promoter methylation of TSLC1 and tumor suppression by its gene product in human prostate cancer. Jpn J Cancer Res 2002; 93: 605-9.
11. Steenbergen RD, Kramer D, Braakhuis BJ et al. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst 2004; 96: 294-305.
12. Uchino K, Ito A, Wakayama T et al. Clinical implication and prognostic significance of the tumor suppressor TSLC1 gene detected in adenocarcinoma of the lung. Cancer 2003; 98: 1002-7.
13. Ito A, Okada M, Uchino K et al. Expression of the TSLC1 adhesion molecule in pulmonary epithelium and its down-regulation in pulmonary adenocarcinoma other than bronchioloalveolar carcinoma. Lab Invest 2003; 83: 1175-83.
14. Hirohashi S, Kanai Y. Cell adhesion system and human cancer morphogenesis. Cancer Sci 2003; 94: 575-81.
15. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-17.
16. Travis WD, Colby TV, Corrin B et al. Histological Typing of Lung and Pleural Tumours, 3rd edn. Berlin: Springer, 1999.
17. Noguchi M, Morikawa A, Kawasaki M et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995; 75: 2844-52.
18. The Japan Lung Cancer Society. General Rule for Clinical and Pathological Record of Lung Cancer. Tokyo, Japan: Kanehara and Co., 1999.
19. Yageta M, Kuramochi M, Masuda M et al. Direct association of TSLC1 and DAL-1, two distinct tumor suppressor proteins in lung cancer. Cancer Res 2002; 62: 5129-33.
20. Goto A, Niki T, Moriyama S et al. Immunohistochemical study of Skp2 and Jab1, two key molecules in the degradation of P27, in lung adenocarcinoma. Pathol Int 2004; 54: 675-81.
21. Ishida H, Irie K, Itoh T, Furukawa T, Tokunaga O. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Cancer 1997; 80: 1034-45.
22. Ito T, Shimada Y, Hashimoto Y et al. Involvement of TSLC1 in progression of esophageal squamous cell carcinoma. Cancer Res 2003; 63: 6320-6.
23. Moriya Y, Niki T, Yamada T, Matsuno Y, Kondo H, Hirohashi S. Increased expression of laminin-5 and its prognostic significance in lung adenocarcinomas of small size. An immunohistochemical analysis of 102 cases. Cancer 2002; 91: 1129-41.
24. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64: 8919-23.
25. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
26. Junker K. Prognostic factors in stage I/II non-small cell lung cancer. Lung Cancer 2001; 33: S17-24.